MAR 1 5 2004

PTO/SB/21 (01-03) Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number RAGEN Application Number 10/732,838 TRANSMITTAL Filing Date December 10, 2003 **FORM** First Named Inventor Chen Art Unit (to be used for all correspondence after initial filing) **Examiner Name** Attorney Docket Number 21101 US2 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication Fee Transmittal Form Drawing(s) to Group Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to Group Petition (Appeal Notice, Brief, Reply Brief) Amendment/Reply Petition to Convert to a **Proprietary Information** After Final Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Terminal Disclaimer **Extension of Time Request** Identify below): Request for Refund **Express Abandonment Request** CD, Number of CD(s) Information Disclosure Statement Remarks Certified Copy of Priority Document(s) PATO Form 1449; References Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Eileen M. Ebel Individual Signature Date March 11, 2004 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on this date March 11, 2004 Typed or printed Eileen M. Ebel March 11, 2004 Date Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventor(s) Chen, et al.

Group:

Serial No. 10/732,838, filed December 10, 2003

Examiner:

Docket No.: 21101 US2

For: 5-SUBSTITUTED-SIX-MEMBERED HETEROAROMATIC GLUCOKINASE

ACTIVATORS

INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110 March 11, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents B1-B6 and C1-C13 listed on Form PTO-1449 are enclosed. Documents A1-A20 are not enclosed because they are US Patents.

Also, Applicants note US Application numbers 10/616,359 and 10/421,109.

Consideration of all the documents cited on Form PTO-1449 is requested.

Serial No. 10/732,838

Filed: December 10, 2003

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits for the above application, it is believed that no fee is due. If any fees are required, please charge our deposit account no. 08-2525.

Respectfully submitted,

Attorney for Applicant(s)

Eileen M. Ebel (Reg. No. 37,316)

340 Kingsland Street

Nutley, New Jersey 07110 Telephone: (973) 235-4391

Telefax: (973) 235-2363

139703

MAR 1 5 2004

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

(Use several sheets if necessary)

Complete if Known					
Application Number	10/732,838				
Filing Date	December 10, 2003				
First Name Inventor	Chen				
Group Art Unit					
Examiner Name					
Attorney Docket Number	21101 US2				

.07					Examiner Name			
Sheet	et 1		of 1		Attorney Docket Number	21101	US2	
					ENT DOCUMENTS			
Examiner Initials'			U.S. Patent Docume Number		Name of Patentee or Applicant of Cited Document		Date of Publication of Cited document MM-DD-YYYY	
	A1	5,16	9,951		Sutter, et al.		12-08-1992	
	A2	5,11	3,013		Powell, et al.		05-12-1992	
	A3	3,43	1,301		Focella, et al.		03-04-1969	
	A4	3,77	6,917		Mann, et al.		12-04-1973	
	A5	5,55	6,859		Johnson	09-17-1996		
	A6	6,48	6,184		Kester, et al.	11-26-2002		
	A7		0,846		Bizzarro, et al.		08-26-2003	
	A8	6,52	8,543		Bizzarro, et al.			
	A9	6,32	0,050		Bizzarro, et al.	11-20-2001		
	A10	6,35	3,111		Corbett, et al.	· · · · · · · · · · · · · · · · · · ·		
	A11	6,48	9,485		Bizzarro, et al.		12-03-2002	
	A12		9,232		Sidduri		04-09-2002	
	A13	6,38	8,088		Sidduri		05-14-2002	
· · · · · · · · · · · · · · · · · · ·	A14	6,44	1,180		Sidduri		08-27-2002	
	A15	6,38	4,220		Corbett, et al.		05-07-2002	
	A16	6,38	8,071		Mahaney	05-14-2002		
	A17		1,184		Corbett, et al.	08-27-2002		
	A18	6,43	3,188		Corbett, et al.	08-13-2002		
	A19	6,54	5,155		Corbett, et al.	08-08-2003		
	A20	6,44	8,399		Corbett, et al.		09-10-2002	
					ATENT DOCUMENTS			
Examiner Initials'	Cite No.1	Foreig Office	gn Patent Docum Number	Kind Code	Name of Patentee or Applicant of Cited Docum	(te of Publication of Cited Document MM-DD-YYYY	T ⁶
	B1	EP 5	666 138		Hodogaya Chemical Co., Ltd.	10-	10-20-1993	
	B2	WO	00/26202		Pharmacia & Upjoh S.P.A.	n 05-	05-11-2000	
	В3	WO	00/58293		F. Hoffmann-La Roche AG	10-	10-05-2000	
	B4	WO	02/08209		F. Hoffmann-La Roche AG	01-	01-31-2002	
	B5	SP 1	,436,502		Robert G.W. Spicke et al.	ett, 05-	05-19-1976	
	B6	DE 2	249 241		Farbenfabriken	07-	-13-1912	
		<u> </u>						
Examiner	Examiner Date Considered							

Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *Inter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation or abstract is attached.

1011	3	Si	ubstitute f	or form 1449A/PTO	Com	plete if Known
	ÝÇ,	FORMA	ΓΙΟΝ	DISCLOSURE	Application Number	10/732,838
MAR 1	5 200% S	ATEMENT BY APPLICANT		Y APPLICANT	Filing Date	December 10, 2003
MAR !	3 2004	<u> </u>		First Name Inventor	Chen	
H	á	(Use sever	(Use several sheets if necessary)	Group Art Unit		
TRAD	- 0 200				Examiner Name	
	Sheet	2	Of	2	Attorney Docket Number	21101 US2

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials'	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	C1	COLOWICK, S.P., The Enzymes, Vol. 9 (P. Boyer, ed.) Academic	
		Press, New York, NY, pg. 1-48 (1973)	
	C2	CHIPKIN, et. al., in Joslin's Diabetes (C.R. Kahn and G.C. Wier, eds.),	
•		Lea and Febiger, Philadelphia, PA, pg. 97-115 (1994)	
	C3	PRINTZ, et. al., Ann. Rev. Nutrition, Vol. 13 (R.E. Olson, D.M. Bier,	
		and D.B. McCormick, eds.) Annual Review Inc, Palo Alto, CA pp.	
		463-496 (1993)	
	C4	MEGLASSON, et. al., Amer. J. Physiol., 246, E1-E13 (1984)	
	C5	GRUPE, et. al., Cell 83, 69-78, (1995)	
	C6	FERRE, et al., FASEB J., 10, 1213-1218 (1996)	
	C7	LIANG, et al., Biochem. J. 309, 167-173 (1995)	
	C8	GLASER, et. al. New England J. Med. 338, 226-230 (1998)	
	C9	RODIER, et. al., Acta Crystallogr., C46 (1990) pp. 154-156	
ng. 177	C10	ROBERT, J. M. H., et. al., Eur J. Med. Chem. Vol. 29, (1994), pp. 841-	
	C11	SDICKETT at al. Fan I Mad Cham Chiming Thomas vising Vol	╁
	C11	SPICKETT, et. al., Eur. J. Med. ChemChimica Therapeutica, Vol. 11(1), (1976), pp. 7-12	
	C12	BHAT, A. R., et. al., J. Inst. Chemists (India), Vol. 61, 1989, pp. 134-136	
	C13	SPIELMAN, M.A., et. al., J. Am. Chem. Soc., 70 (1948), pp. 4189-4191	
			<u> </u>
			T
·	<u> </u>		T
	+		
	<u> </u>		
			
_			+
:	1		1
	-		†-
· -	+		+-
			+
			+-
			╁┈
Examiner		DATE	
Signature		CONSIDERED	

Signature CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. *Applicant is to place a check mark here if English language Translation or abstract is attached.

139699